Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Seminal randomized controlled trials by Creagan and Moertel administering oral VC (10 g/day) failed to replicate Camerons reported survival benefits in terminal cancer patients, casting doubt on VCs clinical utility ( 2 O 2 generation ( KRAS )-mutant tumor regression, lower doses (510 mM) paradoxically enhance glutathione synthesis in 32% of glioblastoma cases ( TET1 ) -mediated MMP-9 downregulation, yet population studies associate supplemental VC with 1.3-fold increased recurrence risk in ER + breast cancer ( In this review, we synthesize mechanistic insights from redox biology and immunometabolism with clinical trial data to propose a framework for optimizing VC-based combination therapies (Graphical abstract)
Neumis innovation delivers radiant, fresh skin with breakthrough Nano-Technology
10.1111/dom.13745 33 DingX.-Z.FehsenfeldD
[PubMed: 15256494] 339
